 | Up a level |
Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna-Maria, Robrecht, Sandra, Samoylova, Olga, Liberati, Anna M., Pinilla-Ibarz, Javier, Opat, Stephen, Sivcheva, Liliya, Le Du, Katell, Fogliatto, Laura M., Niemann, Carsten U., Weinkove, Robert, Robinson, Sue, Kipps, Thomas J., Tausch, Eugen, Schary, William, Ritgen, Matthias, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael and Fischer, Kirsten (2020). Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol., 21 (9). S. 1188 - 1201. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488
Goede, Valentin, Fischer, Kirsten, Busch, Raymonde, Engelke, Anja, Eichhorst, Barbara, Wendtner, Clemens M., Chagorova, Tatiana, de la Serna, Javier, Dilhuydy, Marie-Sarah, Illmer, Thomas, Opat, Stephen, Owen, Carolyn J., Samoylova, Olga, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Doehner, Hartmut, Langerak, Anton W., Ritgen, Matthias, Kneba, Michael, Asikanius, Elina, Humphrey, Kathryn, Wenger, Michael and Hallek, Michael (2014). Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. N. Engl. J. Med., 370 (12). S. 1101 - 1111. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406